Ligence is proud to announce that we have successfully raised $3 million in our latest funding round, a pivotal step in our mission to revolutionize cardiac healthcare. As innovators in the field of cardiac ultrasound, we are dedicated to making heart disease monitoring more accessible and cost-effective for patients and healthcare providers alike. Traditional cardiac ultrasound testing is burdened by manual processes, with up to 85% of test time consumed by time-intensive tasks such as measurement and report writing. With our cutting-edge technology, we automate these laborious aspects, enabling faster and more efficient analysis without compromising the quality of patient care. The funding we have secured will be used to further enhance our automated analysis algorithms, expand our team of talented engineers and medical experts, and broaden our market reach. As we look toward the future, our goal is to ensure that cardiac ultrasound is not just affordable but is also highly dependable, providing critical insights for both prevention and monitoring of heart disease. This investment marks a significant milestone for Ligence and reinforces our commitment to improving cardiovascular health worldwide. With this innovative approach to cardiac ultrasound, we anticipate transforming the landscape of heart disease detection and management, ultimately saving lives through timely and accurate interventions. We are excited to embark on this journey and are grateful to our investors for their trust and support.








